AI in Healthcare

What if the first psychedelic drug approval doesn’t just treat depression — but sets the standard for how AI and medicine co-evolve? The drug’s intense subjective effects break clinical trial blinding, making efficacy hard to measure. And as Harvard’s Steven Hyman warned, early missteps could collapse trust across the entire field. This isn’t just about psychedelics — it’s about how AI models trained on traditional data will fail if they don’t account for the unblinded, experience-driven nature of next-gen therapies. The path to responsible innovation is not faster approval — it’s smarter, more adaptive systems. Source: https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/?utm_campaign=rss View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request. MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy. Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member. Associate Broker. George Arnold Alexander III, MPA Director, ALEX Companies Associate Broker, Alexander Tiffany Southwest, LLC dba ALEX.realestate, et.al. Texas License #574878-B · Broker License #565194-BB Broker, ALEX Real Estate · North Carolina License #367733 Independent Broker, ALEX Real Estate · Colorado License #II.100112456 [email protected] · +1 713.918.9951